Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
| Autor: | Jaskaran Singh, Jennifer L. Payne, Jorge A. Quiroz, David A. Luckenbaugh, Kirk D. Denicoff, Carlos A. Zarate, Dennis S. Charney, Husseini K. Manji |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Lithium (medication) Pilot Projects Lithium Placebo Drug Administration Schedule Bipolar II disorder Pramipexole Double-Blind Method Antimanic Agents Dopamine receptor D3 Internal medicine medicine Humans Benzothiazoles Nerve Growth Factors Bipolar disorder Psychiatry Biological Psychiatry Depression (differential diagnoses) Dose-Response Relationship Drug Receptors Dopamine D2 Valproic Acid Receptors Dopamine D3 Middle Aged medicine.disease Antidepressive Agents Thiazoles Dopamine Agonists Antidepressant Drug Therapy Combination Female Psychology medicine.drug |
| Zdroj: | Biological Psychiatry. 56:54-60 |
| ISSN: | 0006-3223 |
| Popis: | Background The original serotonergic and noradrenergic hypotheses do not fully account for the neurobiology of depression or mechanism of action of effective antidepressants. Research implicates a potential role of the dopaminergic system in the pathophysiology of bipolar disorder. The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression. Methods In a double-blind, placebo-controlled study, 21 patients with DSM-IV bipolar II disorder, depressive phase on therapeutic levels of lithium or valproate were randomly assigned to treatment with pramipexole ( n = 10) or placebo ( n = 11) for 6 weeks. Primary efficacy was assessed by the Montgomery-Asberg Depression Rating Scale. Results All subjects except for one in each group completed the study. The analysis of variance for total Montgomery-Asberg Depression Rating Scale scores showed a significant treatment effect. A therapeutic response (>50% decrease in Montgomery-Asberg Depression Rating Scale from baseline) occurred in 60% of patients taking pramipexole and 9% taking placebo ( p = .02). One subject on pramipexole and two on placebo developed hypomanic symptoms. Conclusions The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect